WO2003045370A1 - Pharmaceutical composition for treating obesity - Google Patents

Pharmaceutical composition for treating obesity Download PDF

Info

Publication number
WO2003045370A1
WO2003045370A1 PCT/IB2001/002227 IB0102227W WO03045370A1 WO 2003045370 A1 WO2003045370 A1 WO 2003045370A1 IB 0102227 W IB0102227 W IB 0102227W WO 03045370 A1 WO03045370 A1 WO 03045370A1
Authority
WO
WIPO (PCT)
Prior art keywords
sbs
pharmaceutical composition
treatment
salt
obesity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2001/002227
Other languages
French (fr)
Inventor
Avner Shenfeld
Meir Shinitzky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LEAN-EX Ltd
Original Assignee
LEAN-EX Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LEAN-EX Ltd filed Critical LEAN-EX Ltd
Priority to ES01274819T priority Critical patent/ES2259650T3/en
Priority to PCT/IB2001/002227 priority patent/WO2003045370A1/en
Priority to AT01274819T priority patent/ATE318591T1/en
Priority to DE60117472T priority patent/DE60117472T2/en
Priority to AU2002220943A priority patent/AU2002220943A1/en
Priority to EP01274819A priority patent/EP1455774B1/en
Publication of WO2003045370A1 publication Critical patent/WO2003045370A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Definitions

  • the present invention is in the field of treatment and prevention of obesity and atherosclerosis in human and non-human animals.
  • Lipids are stored in the body mostly as fat under the skin and consumption of lipids and carbohydrates beyond the metabolic need leads to fattening.
  • the associated medical and aesthetic problem, are a major concern in modern society.
  • MEDIC A hexadecane derivative
  • U.S. patent 5,602,104 to Shinitzky et al. discloses a dietary supplement for the treatment of obesity.
  • the dietary suplements that is mentioned is the compound N,N' sebacoyl bis-sarcoeine-ethylester [S(Sar) 2 ] having the formula (CH 2 ) 8 -[CO-N(CH 3 )-CH 2 -COOH] 2 .
  • the present invention provides a new SBS formulation wherein the SBS is provided in the form of a salt, with the salt forming anion being L-arginine and or
  • the present invention thus provides a method for the treatment of obesity comprising administering to a subject an effective amount of SBS in the form of a salt, with the salt forming anion being L-arginine or L-lysine.
  • the method of the invention is applicable to both human and non-human animals.
  • the SBS can be administered, in accordance with the invention, parenterally, orally, topically, with oral administration being preferred.
  • a suitable oral administration is a capsule or a pill, but other oral administration formulations, such as a drink or a syrup, are not excluded.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising, as its active ingredient, an effective amount of SBS in a salt form, with the salt- forming anion being L-arginine or L-lysine.
  • a particular use of the pharmaceutical composition is in the treatment of obesity.
  • the term "pharmaceutical composition” should be understood in the broadest sense and includes, in its scope, a pharmaceutical composition intended as a drug that is indicated for treatment of a certain disease or condition, a cosmetic composition or another composition intended to be used in a non-medicated fashion, e.g. a composition sold over the counter (OTC) without a implied indication, as well as a composition intended for veterinary use.
  • OTC over the counter
  • the present invention provides use of SBS in the form of a salt, with the salt forming anion being L-arginine or L-lysine, for the preparation of a pharmaceutical composition, particularly a pharmaceutical composition for the treatment of obesity.
  • the effective amount is an amount which is effective to cause the treated subject, upon repeated administration, to reduce the amount of the fat in its body and hence its weight.
  • the effective amount depends on factors such as the administration regime, for example whether the pharmaceutical composition is administered to the individual several times, e.g. twice daily, once a day, once every two days, once every week, etc. Additionally, the effective amount may also depend on the weight of the treated individual, on its gender, on age or on a number of other physiological parameters. In addition, the effective amount may also depend on other factors such as diseases the individual has, other drug treatments the individual receives, etc.
  • the present invention also provides a use of SBS in combination with L-Arginine or L-lysine, for the preparation of a pharmaceutical composition for the treatment of obesity.
  • SBS can be applied to both human and non-human animals and be administered both topically and orally in a preferably but not limited to capsule form.
  • the invention will be illustrated by a pharmaceutical composition in which L-arginine is used as the salt-forming anion.
  • L-arginine and L-lysine are chemically similar, the results shown below demonstrate the superiority of the L-arginine-comprising composition of the invention over other compositions of SBS, permits to predict that compositions of the invention with L-lysine the salt-forming anion, will behave in a similar manner.
  • Fig 2 shows serum SBS level in rabbits after a single oral dose of SBS in the form of floating tablets. It can be seen that it reached maximal levels at a somewhat lower rate than that seen in Fig. 1 and also a lower maximal line.
  • Fig 3 shows serum SBS level in rabbits after a single oral dose of SBS in the form of immediate release tablets. It can be seen that the peak of SBS is reached only after about 5 Oh.
  • Fig 4 shows serum SBS level in rabbits after a single oral dose of SBS in the form of sustained release tablets. It is demonstrated that immediately after the SBS was given, the SBS level reach its peak (lower than demonstrated in Fig 2) and begins its decline immediately after.
  • Figs 5 and 6 show serum SBS level in rabbits after a single oral dose of SBS administered in enterocoated tablets and in the form of sodium salt solution, respectively. It can be seen that the amount of SBS rises very slowly to its highest level (much lower than the rate seen in Fig. 1) and remains in a constant level for a long time. Furthermore, the maximal level is dramatically lower than that seen in Fig. 1.
  • Tmax Time of maximum observed concentration.
  • T last Time of last measurable (non-zero) concentration.
  • AUC Area under the curve.
  • Vz, Vz/F Volume of distribution based on the terminal phase.
  • M T last: Mean residence time from the time of dosing (Dosing_time) to the last measurable concentration, for infusion models.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

A salt of N,N' sebacoyl bis-sarcosine [S(Sar)2] having the formula (CH2)8-[CO-N(CH3)-CH2-COOH]2 (SBS) with L-arginine or L-lysine is used for the treatment of obesity.

Description

PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY
FIELD OF THE INVENTION
The present invention is in the field of treatment and prevention of obesity and atherosclerosis in human and non-human animals.
BACKGROUND OF THE INVENTION Lipids are stored in the body mostly as fat under the skin and consumption of lipids and carbohydrates beyond the metabolic need leads to fattening. The associated medical and aesthetic problem, are a major concern in modern society.
Apart from surgery and dietary means, there is a desire for drugs which will reduce fat accumulation by inhibiting lipid and lipoproteins in the liver. The most potent drug, from the group of β,β' tetrametyl substituted α,ω dicarboxylic acids (MEDIC A), was found to be the hexadecane derivative (MEDIC A 16). It was demonstrated that MEDICA, which is a non-naturally occurring fatty acid, could inhibit biosynthetic pathways of triglycerides and cholesterol in the liver.
U.S. patent 5,602,104 to Shinitzky et al. discloses a dietary supplement for the treatment of obesity. Among the dietary suplements that is mentioned is the compound N,N' sebacoyl bis-sarcoeine-ethylester [S(Sar)2] having the formula (CH2)8-[CO-N(CH3)-CH2-COOH]2.
SUMMARY OF THE INVENTION
The present invention provides a new SBS formulation wherein the SBS is provided in the form of a salt, with the salt forming anion being L-arginine and or
L-lysine. In addition to serving as a source for the nutritionally important amino acid - L-arginine or L-lysine, this salt formulation adds in a synergistic manner a clinically proved absorption of the SBS. By a first of its aspects, the present invention thus provides a method for the treatment of obesity comprising administering to a subject an effective amount of SBS in the form of a salt, with the salt forming anion being L-arginine or L-lysine. The method of the invention is applicable to both human and non-human animals. The SBS can be administered, in accordance with the invention, parenterally, orally, topically, with oral administration being preferred. A suitable oral administration is a capsule or a pill, but other oral administration formulations, such as a drink or a syrup, are not excluded.
By another of its aspects the present invention provides a pharmaceutical composition comprising, as its active ingredient, an effective amount of SBS in a salt form, with the salt- forming anion being L-arginine or L-lysine. A particular use of the pharmaceutical composition is in the treatment of obesity. As will be appreciated, the term "pharmaceutical composition" should be understood in the broadest sense and includes, in its scope, a pharmaceutical composition intended as a drug that is indicated for treatment of a certain disease or condition, a cosmetic composition or another composition intended to be used in a non-medicated fashion, e.g. a composition sold over the counter (OTC) without a implied indication, as well as a composition intended for veterinary use.
By another of its aspects the present invention provides use of SBS in the form of a salt, with the salt forming anion being L-arginine or L-lysine, for the preparation of a pharmaceutical composition, particularly a pharmaceutical composition for the treatment of obesity.
The effective amount is an amount which is effective to cause the treated subject, upon repeated administration, to reduce the amount of the fat in its body and hence its weight. As will be appreciated, the effective amount depends on factors such as the administration regime, for example whether the pharmaceutical composition is administered to the individual several times, e.g. twice daily, once a day, once every two days, once every week, etc. Additionally, the effective amount may also depend on the weight of the treated individual, on its gender, on age or on a number of other physiological parameters. In addition, the effective amount may also depend on other factors such as diseases the individual has, other drug treatments the individual receives, etc.
In another aspect, the present invention also provides a use of SBS in combination with L-Arginine or L-lysine, for the preparation of a pharmaceutical composition for the treatment of obesity. The use of SBS can be applied to both human and non-human animals and be administered both topically and orally in a preferably but not limited to capsule form.
BRIEF DESCRIPTION OF THE DRAWINGS
In order to understand the invention and to see how it may be carried out in practice, one preferred embodiment will now be described, by way of non-limiting example only, with reference to the accompanying drawings, in which:
Fig. 1 shows serum SBS level in rabbits after a single oral dose of SBS in the form of SBS-L-arginine immediate release tablets (n = 4 animals in each case);
Fig. 2 shows the serum SBS level in rabbits after a single oral dose of SBS in the form of floating tables (n = 4 animals in each case);
Fig. 3 shows the serum level in rabbits after a single oral dose of SBS in the form of immediate-release tablets (n = 4 animals in each case);
Fig. 4 shows the serum SBS level in rabbits after a single oral dose of SBS in the form of sustained release tablets (n = 4 animals in each case); Fig. 5 shows the serum SBS level in rabbits after a single dose of SBS in the form of enterocoating tablets (n = 4 animals in each case); and
Fig. 6 shows the serum SBS level in rabbits after a single dose of SBS in the form of SBS-Na salt solution (n = 4 animals in each case).
DETAILED DESCRIPTION OF THE INVENTION In the Example bellow, the invention will be illustrated by a pharmaceutical composition in which L-arginine is used as the salt-forming anion. As L-arginine and L-lysine are chemically similar, the results shown below demonstrate the superiority of the L-arginine-comprising composition of the invention over other compositions of SBS, permits to predict that compositions of the invention with L-lysine the salt-forming anion, will behave in a similar manner.
EXAMPLE COMPARATIVE PHARMACOKINETIC EVALUATION OF DIFFERENT SBS FORMULATIONS (ORAL DOSAGE FORMS) IN RABBITS
36 New Zealand male rabbits (4 animals per Formulation's group), 4-6 months old, 2.7-2.9 kg body weight, were given orally the tested tablets, (see Table 1 below) in the morning, after a night of starvation. Blood samples were collected from an ear vein into serum tubes at different time points up ranging from 15 mins. to 7 days after single-dose administration: 15 min, 30 min, 45 min, lh, 1.5 h, 2h, 4h, 6h, 8h, 24h, 48h, 72h, 96h, 120h, 144h, 168h. Serum was separated by centrifugation. SBS concentration in rabbit's serum was tested by analytical HPLC validated method with sensitivity of 0.5 to 1 ug/ml. Pharmacokinatic analysis was calculated using the Extravascular (model 200) noncompartmental analysis (NCA) of Win NoNlin program (WinNonlin® Copyright ©1998-1999, Pharsight Corporation) version 3.1 build 168.
The maximum SBS serum concentration was achieved using SBS-L-Arginine tablets (16.8 ug/ml). The figures illustrate the results from Tables 2 A and B. Fig 1. shows serum
SBS level in rabbits after a single oral dose of SBS in the form of SBS-L-Arginine immediate release tablets. It can be seen that after a quick increase in the SBS levels, it rapidly and constantly disappears.
Fig 2 shows serum SBS level in rabbits after a single oral dose of SBS in the form of floating tablets. It can be seen that it reached maximal levels at a somewhat lower rate than that seen in Fig. 1 and also a lower maximal line.
Fig 3 shows serum SBS level in rabbits after a single oral dose of SBS in the form of immediate release tablets. It can be seen that the peak of SBS is reached only after about 5 Oh. Fig 4 shows serum SBS level in rabbits after a single oral dose of SBS in the form of sustained release tablets. It is demonstrated that immediately after the SBS was given, the SBS level reach its peak (lower than demonstrated in Fig 2) and begins its decline immediately after.
Figs 5 and 6 show serum SBS level in rabbits after a single oral dose of SBS administered in enterocoated tablets and in the form of sodium salt solution, respectively. It can be seen that the amount of SBS rises very slowly to its highest level (much lower than the rate seen in Fig. 1) and remains in a constant level for a long time. Furthermore, the maximal level is dramatically lower than that seen in Fig. 1.
Tables referred to above, are shown below. In these tables the following abbreviations will be used to denote the following pharmacokinetic parameters:
Tmax: Time of maximum observed concentration.
Cmax: Concentration corresponding to Tmax.
T last: Time of last measurable (non-zero) concentration.
C last: Concentration corresponding to Tlast. Tι/2: Half-life time.
AUC: Area under the curve.
Vz, Vz/F: Volume of distribution based on the terminal phase.
CL, CL/F: Total body clearance.
M T last: Mean residence time from the time of dosing (Dosing_time) to the last measurable concentration, for infusion models.
Table 1 - SBS tablet formulations
Figure imgf000007_0001
Table 2. A. Model-independent pharmacokinetic parameters for SBS following single oral administration of different tablet forms in NZ Rabbits
Figure imgf000008_0001
Table 2. B. Model-independent pharmacokinetic parameters for SBS following single oral administration of different dosage forms in NZ Rabbits
Figure imgf000008_0002

Claims

CLAIMS:
1. A method for the treatment of obesity comprising administrating to a subject N,N' sebacoyl bis-sarcoeine-ethylester [S(Sar)2] having the formula (CH2)8-[CO-N(CH3)-CH2-COOH]2 (SBS) in the form of a salt with L-Arginine or L-lysine as the salt-forming anion.
2. A method according to Claim 1, wherein the administration is oral.
3. A method according to Claim 2, wherein the SBS is administered in the form of a pill or a capsule.
4. A method according to Claim 1, wherein the SBS is administered to treat obesity.
5. A method according to Claim 1, wherein the subject is a non-human animal.
6. A method according to Claim 1, wherein the subject is a human.
7. A pharmaceutical composition comprising an effective amount of N,N' sebacoyl bis-sarcoeine-ethylester [S(Sar)2] having the formula
(CH2)8-[CO-N(CH3)-CH2-COOH]2 (SBS) in the form of a salt with the salt forming anion being L-Arginine or L-lysine.
8. A pharmaceutical composition according to Claim 7, for the treatment of obesity.
9. A pharmaceutical composition according to Claim 8, for oral administration.
10. A pharmaceutical composition according to Claim 9, in the form of a pill or a capsule.
11. A pharmaceutical composition according to Claim 7, for use in the treatment of obesity.
12. A pharmaceutical composition according to Claim 11, for the treatment of a non-human animal.
13. A pharmaceutical composition to Claim 9, for the treatment of a human.
14. Use of N,N' sebacoyl bis-sarcoeine-ethylester [S(Sar)2] having the formula (CH2)8-[CO-N(CH3)-CH2-COOH]2 (SBS) in a salt form with L-Arginine or L-lysine as the salt-forming anion, for the preparation of a pharmaceutical composition for the treatment of obesity. 5
15. Use according to Claim 14, for the preparation of an oral pharmaceutical composition.
16. Use according to Claim 15, for the preparation of a pharmaceutical composition.
17. Use according to Claim 14, for the preparation of a pharmaceutical l o composition for the treatment of obesity.
18. Use according to Claim 14, for the preparation of a pharmaceutical composition for the treatment of a non-human animal.
19. Use according to Claim 14, for the preparation of a pharmaceutical composition for human use.
15
PCT/IB2001/002227 2001-11-26 2001-11-26 Pharmaceutical composition for treating obesity Ceased WO2003045370A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
ES01274819T ES2259650T3 (en) 2001-11-26 2001-11-26 PHARMACEUTICAL COMPOSITION TO TREAT OBESITY.
PCT/IB2001/002227 WO2003045370A1 (en) 2001-11-26 2001-11-26 Pharmaceutical composition for treating obesity
AT01274819T ATE318591T1 (en) 2001-11-26 2001-11-26 PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY
DE60117472T DE60117472T2 (en) 2001-11-26 2001-11-26 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GRAVITY
AU2002220943A AU2002220943A1 (en) 2001-11-26 2001-11-26 Pharmaceutical composition for treating obesity
EP01274819A EP1455774B1 (en) 2001-11-26 2001-11-26 Pharmaceutical composition for treating obesity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2001/002227 WO2003045370A1 (en) 2001-11-26 2001-11-26 Pharmaceutical composition for treating obesity

Publications (1)

Publication Number Publication Date
WO2003045370A1 true WO2003045370A1 (en) 2003-06-05

Family

ID=11004216

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/002227 Ceased WO2003045370A1 (en) 2001-11-26 2001-11-26 Pharmaceutical composition for treating obesity

Country Status (6)

Country Link
EP (1) EP1455774B1 (en)
AT (1) ATE318591T1 (en)
AU (1) AU2002220943A1 (en)
DE (1) DE60117472T2 (en)
ES (1) ES2259650T3 (en)
WO (1) WO2003045370A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004031214A1 (en) * 2002-10-07 2004-04-15 National Institute Of Advanced Industrial Science And Technology Fine spherical particles with satisfactory molecular orientation, spherical microcapsules comprising the same, and processes for producing these
WO2007013062A1 (en) * 2005-07-25 2007-02-01 Lean-Ex Ltd. Composition and method for weight maintenance

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0066934A1 (en) * 1981-06-09 1982-12-15 "PHARLYSE", Société Anonyme Nitrofurantoin salts, their preparation and their use
EP0140492A1 (en) * 1983-09-28 1985-05-08 Warner-Lambert Company L-arginine isoxicamate
WO1993021913A1 (en) * 1992-04-28 1993-11-11 Senyorina Ltd. Anti-obesity drugs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0066934A1 (en) * 1981-06-09 1982-12-15 "PHARLYSE", Société Anonyme Nitrofurantoin salts, their preparation and their use
EP0140492A1 (en) * 1983-09-28 1985-05-08 Warner-Lambert Company L-arginine isoxicamate
WO1993021913A1 (en) * 1992-04-28 1993-11-11 Senyorina Ltd. Anti-obesity drugs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MOOTE CAROL A: "Ibuprofen arginine in the management of pain: A review.", CLINICAL DRUG INVESTIGATION, vol. 11, no. SUPPL. 1, 1996, pages 1 - 7, XP008005721, ISSN: 1173-2563 *
PRUEKSARITANONT T ET AL: "ABSORPTION OF IOTHALAMATE AFTER ORAL ADMINISTRATION AND ABSORPTION ENHANCEMENT BY AMINO-ACIDS IN DOGS AND RATS", BIOPHARMACEUTICS & DRUG DISPOSITION, vol. 7, no. 5, 1986, pages 463 - 478, XP008005722, ISSN: 0142-2782 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004031214A1 (en) * 2002-10-07 2004-04-15 National Institute Of Advanced Industrial Science And Technology Fine spherical particles with satisfactory molecular orientation, spherical microcapsules comprising the same, and processes for producing these
WO2007013062A1 (en) * 2005-07-25 2007-02-01 Lean-Ex Ltd. Composition and method for weight maintenance

Also Published As

Publication number Publication date
DE60117472D1 (en) 2006-04-27
ATE318591T1 (en) 2006-03-15
AU2002220943A1 (en) 2003-06-10
DE60117472T2 (en) 2006-09-28
ES2259650T3 (en) 2006-10-16
EP1455774A1 (en) 2004-09-15
EP1455774B1 (en) 2006-03-01

Similar Documents

Publication Publication Date Title
AU664511B2 (en) Method of promoting nitrogen retention in humans
CA2784836C (en) Improved method of administering .beta.-hydroxy-.beta.-methylbutyrate (hmb)
AU775078B2 (en) Essential fatty acids in the prevention of cardiovascular events
US11331302B2 (en) Transmucosal delivery of tocotrienol
WO2006034463A2 (en) Herbal supplement to support weight loss
JPWO2004019928A1 (en) Liver disease treatment
JP2003171271A (en) Medicine for glucose tolerance disorder
EP0999832B1 (en) Composition comprising l-carnitine or an alkanoyl l-carnitine and long-chain alkanols
WO2007049818A1 (en) Anti-fatty liver, anti-obesity or hypolipidemic composition
US20040043442A1 (en) Use of betaine in functional products having blood pressure lowering effects
JPH0699310B2 (en) Acetaldehyde antidote
US6441041B1 (en) (-)-hydroxycitric acid for the prevention of osteoporosis
EP1455774A1 (en) Pharmaceutical composition for treating obesity
US20110117070A1 (en) Compositions and methods for treating headache
JPH07118148A (en) Liver cancer prevention agent
CN120583948A (en) Administration of DHB enhances the weight loss benefits of intermittent fasting
US20140024712A1 (en) Acetyl l-carnitine for the preparation of a medicament for the prevention of painful peripheral neuropathy in patients with type 2 diabetes
CN118019529A (en) Methods for inhibiting the progression of oxidative retinal diseases
US20030040507A1 (en) Pharmaceutical composition comprising ifosfamide and carnitine
US6441039B1 (en) Gastro-intestinal adverse effect-free composition comprising an L-carnitine replacement
ES2425045T3 (en) Acetyl-L-carnitine for the prevention of painful peripheral diabetic neuropathy
JPH0319208B2 (en)
JPH06102624B2 (en) Anti-arrhythmic drugs of non-heart origin
WO2003022263A1 (en) Pharmaceutical composition comprising gamma-butyrobetaine for stimulating the sexual activity and potency
JP2000327571A (en) Anti-itching composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001274819

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001274819

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWG Wipo information: grant in national office

Ref document number: 2001274819

Country of ref document: EP